---
title: "Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference | CGEN Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282180740.md"
description: "Compugen Ltd. (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45-9:25 AM ET. A live webcast will be available on their Investor Relations website, with a replay following the event. Compugen focuses on cancer immunotherapy and utilizes AI/ML for drug target discovery, with several programs in various stages of development, including COM902 and rilvegostomig. Compugen's shares are traded on Nasdaq and the Tel Aviv Stock Exchange under CGEN."
datetime: "2026-04-09T03:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282180740.md)
  - [en](https://longbridge.com/en/news/282180740.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282180740.md)
---

# Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference | CGEN Stock News

, /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation will take place on Monday, April 13, 2026, at 8:45-9:25 AM ET.

A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.

**About Compugen**

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

**Company contact:  
**Investor relations  
Email: ir@cgen.com  
Tel: +1 (628) 241-0071

SOURCE Compugen Ltd.

### Related Stocks

- [CGEN.US](https://longbridge.com/en/quote/CGEN.US.md)

## Related News & Research

- [Compugen Reports First Quarter 2026 Results | CGEN Stock News](https://longbridge.com/en/news/286758883.md)
- [How Chubb’s (CB) New Canada Cancer Coverage Launch Could Reframe Its Health Benefits Strategy](https://longbridge.com/en/news/286787301.md)
- [Health Rounds: Widely used asthma drug may improve performance of cancer immunotherapies](https://longbridge.com/en/news/286957357.md)
- [Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K. | SOPH Stock News](https://longbridge.com/en/news/286227729.md)
- [BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests](https://longbridge.com/en/news/286850851.md)